Moffitt Cancer Center Logo
 

Richard Lush, PhD

Where You Are:
Richard Lush, PhD

Office  (813) 745-1827

Education And Training


Dr. Lush’s work includes directing the Clinical Trials Laboratory core facility, which facilitates and coordinate the clinical and statistical design of phase I and II trials, provides clinical data management of patients on these trials, and collects and nalyzes clinical and laboratory outcome data for these studies, along with providing correlative pharmacokinetic and pharmacodynamic drug analyses for specific protocols.

  • Gray J, Haura EB, Chiappori A, Tanvetyanon T, Williams CC, Pinder-Schenk M, Kish JA, Kreahling JM, Lush RM, Neuger AM, Tetteh LF, Akar A, Zhao X, Schell MJ, Bepler G, Altiok S. A Phase I, Pharmacokinetic, and Pharmacodynamic Study of Panobinostat, an HDAC Inhibitor, Combined with Erlotinib in Patients with Advanced Aerodigestive Tract Tumors. Clin Cancer Res. 2014 Mar;20(6):1644-1655. Pubmedid: 24429877.
  • Komrokji RS, Lancet JE, Swern AS, Chen N, Paleveda J, Lush R, Saba HI, List AF. Combined treatment with lenalidomide and epoetin alfa in lower-risk patients with myelodysplastic syndrome. Blood. 2012 Oct;120(17):3419-3424. Pubmedid: 22936658.
  • Lush RM, Patnaik A, Sullivan D, Papadopoulos KP, Trucksis M, McCrea J, Cerchio K, Li X, Stroh M, Selverian D, Orford K, Ebbinghaus S, Agrawal N, Iwamoto M, Wagner JA, Tolcher A. A single supratherapeutic dose of ridaforolimus does not prolong the QTc interval in patients with advanced cancer. Cancer Chemother Pharmacol. 2012 Oct;70(4):567-574. Pubmedid: 22878520. Pmcid: PMC3456920.
  • Garrett CR, Coppola D, Wenham RM, Cubitt CL, Neuger AM, Frost TJ, Lush RM, Sullivan DM, Cheng JQ, Sebti SM. Phase I pharmacokinetic and pharmacodynamic study of triciribine phosphate monohydrate, a small-molecule inhibitor of AKT phosphorylation, in adult subjects with solid tumors containing activated AKT. Invest New Drugs. 2011 Dec;29(6):1381-1389. Pubmedid: 20644979.
  • Perkins JB, Goldstein SC, Dawson JL, Kim J, Field TL, Partyka JS, Fields KK, Maddox BL, Simonelli CE, Neuger AM, Lush RM, Sullivan DM. Phase I Study of Topotecan, Ifosfamide, and Etoposide (TIME) with autologous stem cell transplant in refractory cancer: pharmacokinetic and pharmacodynamic correlates. Clin Cancer Res. 2011 Dec;17(24):7743-7753. Pubmedid: 22028494.
  • O'Neil BH, Goff LW, Kauh JS, Strosberg JR, Bekaii-Saab TS, Lee RM, Kazi A, Moore DT, Learoyd M, Lush RM, Sebti SM, Sullivan DM. Phase II study of the mitogen-activated protein kinase 1/2 inhibitor selumetinib in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2011 Aug;29(17):2350-2356. Pubmedid: 21519015. Pmcid: PMC3107750.
  • Daud AI, Dawson J, Deconti RC, Bicaku E, Marchion D, Bastien S, Hausheer FA, Lush R, Neuger A, Sullivan DM, Munster PN. Potentiation of a topoisomerase I inhibitor, karenitecin, by the histone deacetylase inhibitor valproic acid in melanoma: translational and phase I/II clinical trial. Clin Cancer Res. 2009 Apr;15(7):2479-2487. Pubmedid: 19318485.
  • Husain K, Francois RA, Hutchinson SZ, Neuger AM, Lush R, Coppola D, Sebti S, Malafa MP. Vitamin E delta-tocotrienol levels in tumor and pancreatic tissue of mice after oral administration. Pharmacology. 2009;83(3):157-163. Pubmedid: 19142032. Pmcid: PMC2834260.
  • Moulder S, Valkov N, Neuger A, Choi J, Lee JH, Minton S, Munster P, Gump J, Lacevic M, Lush R, Sullivan D. Phase 2 study of gemcitabine and irinotecan in metastatic breast cancer with correlatives to determine topoisomerase I localization as a predictor of response. Cancer. 2008 Nov;113(10):2646-2654. Pubmedid: 18823053.
  • Chiappori AA, Haura E, Rodriguez FA, Boulware D, Kapoor R, Neuger AM, Lush R, Padilla B, Burton M, Williams C, Simon G, Antonia S, Sullivan DM, Bepler G. Phase I/II study of atrasentan, an endothelin A receptor antagonist, in combination with paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer. Clin Cancer Res. 2008 Mar;14(5):1464-1469. Pubmedid: 18316570.
  • Mikkelsen T, Lush R, Grossman SA, Carson KA, Fisher JD, Alavi JB, Rosenfeld S. Phase II clinical and pharmacologic study of radiation therapy and carboxyamido-triazole (CAI) in adults with newly diagnosed glioblastoma multiforme. Invest New Drugs. 2007 Jun;25(3):259-263. Pubmedid: 17080256. Pmcid: PMC3963813.
  • Münster P, Marchion D, Bicaku E, Schmitt M, Lee JH, DeConti R, Simon G, Fishman M, Minton S, Garrett C, Chiappori A, Lush R, Sullivan D, Daud A. Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study. J Clin Oncol. 2007 May;25(15):1979-1985. Pubmedid: 17513804.
  • de Lima Lopes G, Chiappori A, Simon G, Haura E, Sullivan D, Antonia S, Langevin M, Lush R, Rocha-Lima CM. Phase I study of carboplatin in combination with gemcitabine and irinotecan in patients with solid tumors: preliminary evidence of activity in small cell and neuroendocrine carcinomas. Cancer. 2007 Apr;109(7):1413-1419. Pubmedid: 17326096.
  • Mirza N, Fishman M, Fricke I, Dunn M, Neuger AM, Frost TJ, Lush RM, Antonia S, Gabrilovich DI. All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients. Cancer Res. 2006 Sep;66(18):9299-9307. Pubmedid: 16982775. Pmcid: PMC1586106.
  • Simon G, Lush R, Gump J, Tetteh L, Williams C, Cantor A, Antonia S, Garrett C, Rocha-Lima C, Fishman M, Sullivan D, Munster P. Sequential oral 9-nitrocamptothecin and etoposide: a pharmacodynamic- and pharmacokinetic-based phase I trial. Mol Cancer Ther. 2006 Aug;5(8):2130-2137. Pubmedid: 16928835.
  • Simon GR, Garrett CR, Olson SC, Langevin M, Eiseman IA, Mahany JJ, Williams CC, Lush R, Daud A, Munster P, Chiappori A, Fishman M, Bepler G, Lenehan PF, Sullivan DM. Increased bioavailability of intravenous versus oral CI-1033, a pan erbB tyrosine kinase inhibitor: results of a phase I pharmacokinetic study. Clin Cancer Res. 2006 Aug;12(15):4645-4651. Pubmedid: 16899614.
  • Samarasena J, Winsor W, Lush R, Duggan P, Xie Y, Borgaonkar M. Individuals Homozygous for the H63D Mutation Have Significantly Elevated Iron Indexes. Dig Dis Sci. 2006 Apr;51(4):803-807. Pubmedid: 16615007.
  • Fishman M, Garrett C, Simon G, Chiappori A, Lush R, Dinwoodie W, Mahany J, Dellaportas A, Cantor A, Gollerki A, Cohen M, Sullivan D. Phase I study of the taxane BMS-188797 in combination with carboplatin administered every 3 weeks in patients with solid malignancies. Clin Cancer Res. 2006 Jan;12(2):523-528. Pubmedid: 16428495.
  • Lush RM, McCune J, Tetteh L, Thompson JA, Mahany JH, Garland L, Suttle AB, Sullivan DM. The absolute bioavailability of oral vinorelbine in patients with solid tumors. Cancer Chemother Pharmacol. 2005 Dec;56(6):578-584. Pubmedid: 16001165.
  • Garrett CR, Fishman MN, Rago RR, Williams CC, Dellaportas AM, Mahany JJ, Lush RM, Dalton WS, Gollerkeri A, Cohen MB, Sullivan DM. Phase I study of a novel taxane BMS-188797 in adult patients with solid malignancies. Clin Cancer Res. 2005 May;11(9):3335-3341. Pubmedid: 15867232.
  • Sood A, Lush R, Geisler J, Shahin M, Sanders L, Sullivan D, Buller R, Sorosky J. Sequential intraperitoneal topotecan and oral etoposide chemotherapy in recurrent platinum-resistant ovarian carcinoma: results of a phase II trial. Clin Cancer Res. 2004 Sep;10(18 Pt 1):6080-6085. Pubmedid: 15447993.
  • Moulder S, Mahany J, Lush R, Rocha-Lima C, Langevin M, Ferrante K, Bartkowski L, Kajiji S, Noe D, Paillet S, Sullivan D. A phase I open label study of the farnesyltransferase inhibitor CP-609,754 in patients with advanced malignant tumors. Clin Cancer Res. 2004;10(21):7127-7135. Pubmedid: 15534083.
  • Rudek MA, Bauer KS, Lush RM, Stinson SF, Senderowicz AM, Headlee DJ, Arbuck SG, Cox MC, Murgo AJ, Sausville EA, Figg WD. Clinical pharmacology of flavopiridol following a 72-hour continuous infusion. Ann Pharmacother. 2003 Oct;37(10):1369-1374. Pubmedid: 14519054.
  • Kusmartsev S, Cheng F, Nefedova Y, Sotomayor E, Lush R, Gabrilovich D. All-trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination. Cancer Res. 2003 Aug;63(15):4441-4449. Pubmedid: 12907617.
  • Rago RP, Einstein A, Lush R, Beer TM, Ko YJ, Henner WD, Bubley G, Merica EA, Garg V, Ette E, Harding MW, Dalton WS. Safety and efficacy of the MDR inhibitor Incel (biricodar, VX-710) in combination with mitoxantrone and prednisone in hormone-refractory prostate cancer. Cancer Chemother Pharmacol. 2003 Apr;51(4):297-305. Pubmedid: 12721757.
  • Grem J, Quinn M, Ismail A, Takimoto C, Lush, III R, Liewehr D, Steinberg S, Balis F, Chen A, Monahan B, Harnold N, Corse W, Pang J, Murphy R, Allegra C, Hamilton J. Pharmacokinetics and pharmacodynamic effects of 5-fluorouracil given as a one-hour intravenous infusion. Cancer Chemother Pharmacol. 2001;42(2):117-125. Pubmedid: 11269737.
  • Sausville E, Arbuck S, Messman R, Headlee D, Bauer K, Lush, III R, Murgo A, Figg W, Lahusen T, Jaken S, Jing X, Roberge M, Fuse E, Kuwabara T, Senderowicz A. Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms. J Clin Oncol. 2001;19(8):2319-2333. Pubmedid: 11304786.
  • Bauer K, Lush, R, Rudek M, Shih C, Sausvile E, Figg W. A high-performance liquid chromatography method using ultraviolet and fluorescence detection for the quantitation of UCN-01, 7-hydroxystaurosporine, from human plasma and saliva. Biomed Chromatogr. 2000;14(5):338-343. Pubmedid: 10960835.
  • Einstein A, Lush, III R, Rago R, Ko Y, Bubley G, Hener W, Beer T, Chatta G, Shepard R, Unger P, Merica E, Ette E, Harding M, Dalton W. A phase II study of the safety, pharmacokinetics and efficacy of Incel (biricodar, VX-710) in combination with mitoxantrone (M) and prednisone (P) in hormone refractory prostate cancer (HRPC). Clin Cancer Res. 1999;5:3836s-3836s. Pubmedid: noPMID.
  • Cho H, Lush, III R, Barlett D, Alexander H, Libutti S, Lee K, Venzon D, Bauer K, Reed E, Figg W. Pharmacokinetics of cisplatin administered by continuous hyperthermic peritoneal perfusion (CHPP) to patients with peritoneal carcinomatosis. J Clin Pharmacol. 1999;39(4):394-401. Pubmedid: 10197298.
  • Sullivan D, Partyka J, Fields K, Goldstein S, Field T, Djulbegovic B, Perkins J, McIssac C, Lush, III R, Dalton W. A Phase I study of intensive-dose melphalan, topotecan and VP-16 phosphate (MTV) followed by autologous stem cell rescue in patients with multiple myeloma. Clin Cancer Res. 1999;5:3734s-3734s. Pubmedid: noPMID.
  • Feuer J, Lush, III R, Venzon D, Duray P, Tompkins A, Sartor O, Figg W. Elevated carcinoembryonic antigen in patients with androgen-independent prostate cancer. J Invest Med. 1998;46(2):66-72. Pubmedid: 9549229.
  • Welles L, Lush, III R, Saville W, Lietzau J, Wyvill K, Pluda J, Humphrey R, Figg W, Feuerstein I, Odom J, Wilson W, Feigal E, Steinberg S, Broder S, Yarchoan R. Phase II trial with dose titration of paclitaxel for the therapy of human immunodeficiency virus-associated Kaposi's sarcoma. J Clin Oncol. 1998;16(3):1112-1121. Pubmedid: 9508198.
  • Senderowicz A, Lush, III R, Stinson S, Kalil N, Villafana L, Hill K, Steinberg S, Figg W, Tompkins A. Phase I trial of continuous infustion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. J Clin Oncol. 1998;16(9):2989-2999. Pubmedid: 9738567.
  • Fuse E, Tanii H, Kurata N, Kobayashi H, Shimada Y, Tamura T, Sasaki Y, Tanigawara Y, Lush, III R, Headlee D, Figg W, Arbuck S, Senderowicz A, Sausville E, Akinaga S, Kuwabara T, Kobayashi S. Unpredicted clinical pharmacology of UCN-01 caused by specific binding to human alpha1-acid glycoprotein. Cancer Res. 1998;58(15):3248-3253. Pubmedid: 9699650.
  • Thibault A, Figg W, Lush, III R, Myers C, Tompkins A, Reed E, Samid D. A phase II study of 5-aza-2'-deoxycitidine (decitidine) in hormone independednt metastic prostate cancer. Tumori. 1998;84(1):87-89. Pubmedid: 9619724.
  • Sausville E, Lush, III R, Headlee D, Smith A, Figg W, Arbuck S, Senderowicz A, Fuse E, Tani H, Kuwabara T, Kobayashi S. Clinical pharmacology of UCN-01: initial observations and comparison to preclinical models. Cancer Chemother Pharmacol. 1998;54-59. Pubmedid: 9750030.
TOOLS:   Font Size small font resizer separator font resizer separator big font resizer